Results 41 to 50 of about 1,060,485 (284)

Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population

Frontiers in Immunology, 2018
Introduction: The complement system is essential for an adequate immune response. Much attention has been given to the role of complement in disease. However, to better understand complement in pathology, it is crucial to first analyze this system under ...
Mariana Gaya da Costa, Felix Poppelaars, Felix Poppelaars, Cees van Kooten, Tom E. Mollnes, Tom E. Mollnes, Tom E. Mollnes, Francesco Tedesco, Reinhard Würzner, Leendert A. Trouw, Leendert A. Trouw, Lennart Truedsson, Mohamed R. Daha, Mohamed R. Daha, Anja Roos, Marc A. Seelen   +15 more
doaj   +1 more source

Structural basis for therapeutic inhibition of complement C5. [PDF]

, 2016
Activation of complement C5 generates the potent anaphylatoxin C5a and leads to pathogen lysis, inflammation and cell damage. The therapeutic potential of C5 inhibition has been demonstrated by eculizumab, one of the world's most expensive drugs. However,
Elmlund, H, Yang I Li, Johnson, S, Nunn, MA, Johnson, Steven, Jore, Matthijs M., Li, Yang I., Susan M Lea, Lea, SM, Natalie M Barber, Devon Sheppard, Lea, Susan M., Li, YI, Sheppard, Devon, Barber, Natalie M., Steven Johnson, Miles A Nunn, Matthijs M Jore, Barber, NM, Elmlund, Hans, Jore, MM, Nunn, Miles A., Sheppard, D, Hans Elmlund   +23 more
core   +1 more source

A fusion protein of the two tick-derived C5 inhibitors OmCI and RaCI: complete C5 inhibition despite strong complement activation

Immunobiology
The complement system must be tightly regulated to prevent tissue damage and disease, yet current C5 inhibitors like the anti-C5 monoclonal antibody Eculizumab – though clinically approved ( e.g. , for paroxysmal nocturnal haemoglobinuria, PNH) - fail to
Sümeyye Erdemci-Evin, Verena Kaupper, Jannik Sichau, Elsa Dopler, Hiba Ghaboosh, Arthur Dopler, Christoph Q. Schmidt   +6 more
doaj   +1 more source

Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy

Emerging Infectious Diseases
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck, Vuokko Nummi, Eira Poikonen, Anna-Elina Lehtinen, Pia Kivelä, Nathalie Friberg, Jukka Torvikoski, Maija Toropainen, Seppo Meri   +8 more
doaj   +1 more source

A serine protease isolated from the bristles of the Amazonic caterpillar, Premolis semirufa, is a potent complement system activator. [PDF]

PLoS ONE, 2015
The caterpillar of the moth Premolis semirufa, commonly named pararama, is found in the Brazilian Amazon region. Accidental contact with the caterpillar bristles causes an intense itching sensation, followed by symptoms of an acute inflammation, which ...
Isadora Maria Villas Boas, Giselle Pidde-Queiroz, Fabio Carlos Magnoli, Rute M Gonçalves-de-Andrade, Carmen W van den Berg, Denise V Tambourgi   +5 more
doaj   +1 more source

A gammaherpesvirus complement regulatory protein promotes initiation of infection by activation of protein kinase Akt/PKB. [PDF]

, 2010
Viruses have evolved to evade the host's complement system. The open reading frames 4 (ORF4) of gammaherpesviruses encode homologs of regulators of complement activation (RCA) proteins, which inhibit complement activation at the level of C3 and C4 ...
Stewart, James P., Stipan, J., Adler, Heiko, James P Stewart, Adler Barbara, Adler, Barbara, Heiko Adler, Beatrix Steer, Barbara Adler, Jonjic Stipan, Stipan Jonjic, Steer, Beatrix, Steer Beatrix, Steer, B., Adler Heiko, Stewart James P., Adler, H., Adler, B., Jonjic, Stipan, James P. Stewart, Stewart, J.P.   +20 more
core   +1 more source

Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan) [PDF]

British Journal of Haematology, 2019
Contains fulltext : 218318.pdf (Publisher’s version ) (Open Access)
Saskia Schols, Miles A. Nunn, Ian Mackie, Wynne Weston‐Davies, Jun‐ichi Nishimura, Yuzuru Kanakura, Nicole Blijlevens, Petra Muus, Saskia Langemeijer   +8 more
openaire   +4 more sources

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment [PDF]

Kidney International, 2020
Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we evaluate the efficacy and safety of ravulizumab in adults with atypical hemolytic uremic syndrome presenting with thrombotic microangiopathy. In this global, phase 3, single arm
Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann, Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Comai, Giorgia, Cappuccilli, Maria, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Luque, Yosu, Menne, Jan, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Gutierréz, Elena, Rodriguez, Paola, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S.   +60 more
openaire   +4 more sources

Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces [PDF]

, 2004
The regulators of complement activation (RCA) are critical to health and disease because their role is to ensure that a complement-mediated immune response to infection is proportionate and targeted.
Krystyna Bromek, Uhrin, D, O'Leary, JM, Xuefeng Wang, Stanislava Uhrinova, Joanne M. O'Leary, Black, GM, Wang, XF, Malgorzata Krych, John P. Atkinson, Uhrinova, S, Dusan Uhrin, Atkinson, JP, Gordon M. Black, Krych, M, Schmitz, C, Paul N. Barlow, Bromek, K, Barlow, PN, Christian Schmitz   +19 more
core   +1 more source

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Blood Advances
: Paroxysmal nocturnal hemoglobinuria (PNH) and primary complement–mediated thrombotic microangiopathy, also known as atypical hemolytic uremic syndrome (aHUS), are hematologic disorders characterized by dysregulation of the complement system leading to ...
Thalia Padilla Kelley, Hannah King, Aditya Malhotra, Thomas G. DeLoughery, Kylee Martens, Joseph J. Shatzel   +5 more
doaj   +1 more source